Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bictegravir/lenacapavir versus Biktarvy in virologically suppressed adults with HIV-1
jRCT2051240046Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Bictegravir + lenacapavir with Biktarvy active control (2 arms). Primary endpoint: Proportion of participants with HIV-1 RNA >= 50 copies/mL at Week 48. Started Jul 2024; status: active, not recruiting.
02
Drugs
bictegravirlenacapaviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on jRCT2051240046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240046.